Related by context. All words. (Click for frequent words.) 70 PXD# 70 Traficet EN 70 MGCD# [001] 70 OXi# 69 Sym# 68 vidofludimus 68 CEQ# 68 ganetespib 67 novel VDA molecule 67 PEG SN# 67 Carfilzomib 67 YONDELIS 67 INCB# [001] 67 CA4P 67 sapacitabine 67 mapatumumab 66 decitabine 66 INCB# [002] 66 HuMax CD4 66 eniluracil 66 vascular disrupting agent 66 Azedra 66 #ME# 66 angiogenesis inhibitor 66 GRN#L 66 Enzastaurin 66 oral prodrug 66 AP# [003] 66 ISIS # 66 PSN# [002] 66 HGS ETR2 66 enzastaurin 66 otelixizumab 66 ProLindac 66 MGCD# [002] 66 Symadex 66 IMC A# 66 orally administered inhibitor 65 Archexin 65 AEG# 65 Atiprimod 65 oral antiviral 65 elacytarabine 65 ELACYT 65 phase IIa clinical 65 fosbretabulin 65 Phase Ib II 65 anti leukemic 65 HGS# 65 Tarvacin TM 65 teriflunomide 65 Phase Ib study 65 CBLC# 65 delafloxacin 65 Phase Ib clinical 65 ENMD # 65 phase IIb clinical 65 BNC# 65 XmAb# 65 tanespimycin 65 pertuzumab 65 Nanobody 65 antitumor efficacy 64 nitazoxanide 64 CIMZIA TM 64 obatoclax 64 tesmilifene 64 Natalizumab 64 Bezielle 64 AVN# [001] 64 ZYBRESTAT 64 seliciclib 64 pan HDAC inhibitor 64 alvespimycin 64 Xanafide 64 eltrombopag 64 Androxal TM 64 CTAP# Capsules 64 PCK# 64 OncoVEX GM CSF 64 pomalidomide 64 Golimumab 64 forodesine 64 Aplidin 64 IRX 2 64 Amrubicin 64 ongoing Phase 1b 64 antiviral activity 64 perifosine 64 ponatinib 64 romidepsin 64 PEG Interferon lambda 64 Vidofludimus 64 HGS ETR1 64 pharmacodynamic 64 ATL# [001] 64 Phase Ib 64 rhIL 7 64 JAK inhibitor 64 tolerability profile 64 Dacogen injection 64 immune modulator 64 IMA# 64 thymalfasin 64 PRT# 64 SCH # 64 pharmacodynamic properties 64 axitinib 64 bavituximab 64 vascular disrupting agents 64 XL# [003] 63 tolerability 63 PDE4 inhibitor 63 pharmacokinetic PK 63 rNAPc2 63 torezolid phosphate 63 SNT MC# 63 CoFactor 63 TG# [003] 63 PS# [001] 63 favorable pharmacokinetic profile 63 BAL# [002] 63 CR# vcMMAE 63 antitumor activity 63 S/GSK# 63 oral JAK1 63 HQK 63 eculizumab 63 ixabepilone 63 Exelixis XL# 63 DACH platinum 63 cilengitide 63 Chemophase 63 Tarceva TM 63 elotuzumab 63 CYC# 63 dose cohorts 63 radezolid 63 BRAF inhibitor 63 R#/MEM # 63 Blinatumomab 63 Omacetaxine 63 PRTX 63 INCB# [003] 63 ataluren 63 Gleevec resistant 63 CLORETAZINE TM VNP#M 63 CCX# 63 Panzem R 63 Virulizin ® 63 lorvotuzumab mertansine 63 BCX# 63 entinostat 63 VAPRISOL 63 subcutaneous formulation 63 Valortim R 63 neratinib 63 Perifosine 63 immunomodulator 63 Azixa 63 indibulin 63 OncoVEX 63 Phase 1b 63 investigational humanized monoclonal antibody 63 JAK1 63 Imprime PGG 63 Alpharadin 63 PF # [001] 63 Factor VIIa 63 Laquinimod 63 Aplidin R 63 Phase IIa trial 63 preclinically 63 ADVEXIN 63 menadione 63 pharmacodynamic PD 63 MLN# 63 Exherin TM 63 C1 INH 62 immunomodulatory 62 pharmacodynamic profile 62 ulimorelin 62 ON #.Na 62 RDEA# 62 HuMax EGFr 62 HspE7 62 milatuzumab 62 brivaracetam 62 Pazopanib 62 Tesetaxel 62 elesclomol 62 oral bioavailability 62 talabostat 62 Panzem R NCD 62 teduglutide 62 vivo efficacy 62 R roscovitine 62 Cloretazine R VNP#M 62 Aurexis 62 BZL# 62 IMGN# 62 Triolex 62 cetuximab Erbitux ® 62 Vandetanib 62 Dasatinib 62 rFIXFc 62 ATL/TV# 62 Alocrest 62 MEK inhibitors 62 cytoprotective 62 huC# DM4 62 nimotuzumab 62 DXL# 62 rBChE 62 posaconazole 62 solithromycin 62 Cloretazine ® 62 EndoTAG TM -1 62 prucalopride 62 Telbivudine 62 Onconase 62 IL #E 62 Denufosol 62 Neulasta ® 62 ZYBRESTAT fosbretabulin 62 Cimzia ® certolizumab pegol 62 pralatrexate 62 PROSTVAC TM 62 pharmacokinetics PK 62 Trastuzumab 62 #D#C# 62 Neuradiab 62 HCD# [002] 62 humanized anti 62 PLX# 62 antiangiogenic 62 ACTEMRA 62 Tarvacin 62 PSMA ADC 62 viral kinetics 62 TNFalpha 62 zanolimumab 62 Phase #b/#a 62 riociguat 62 HIF PHI 62 Bortezomib 62 TBC# 62 Dapagliflozin 62 favorable tolerability 62 safety tolerability pharmacokinetic 62 HuMax CD# 62 CDK inhibitor 62 BRIM2 62 liposomal formulation 62 Rexin G 62 dose cohort 62 mertansine 62 ThGRF 62 ara C 62 tyrosine kinase inhibitor 62 IL# PE#QQR 62 apremilast 62 antibody MAb 62 polymerase inhibitors 62 targeting CD# 62 Phase IIIb clinical 62 radiation sensitizer 62 atacicept 62 anticancer activity 62 Marqibo 62 Phase IIa clinical 62 NXL# 62 MAb 62 methylnaltrexone 62 NEUGENE 62 Targretin 62 Tamibarotene 62 erythropoietic 62 pharmacokinetic profiles 62 MAP# 62 ANA# 62 Proxinium TM 62 Pharmacokinetics PK 62 PROCHYMAL 62 histone deacetylase HDAC inhibitor 62 Cethrin R 62 ruxolitinib 61 receptor tyrosine kinase inhibitor 61 Darinaparsin 61 dose escalation 61 Phase 2a trial 61 GAMMAGARD 61 DermaVir Patch 61 erlotinib Tarceva ® 61 selective modulator 61 nucleoside analog 61 histone deacetylase inhibitor 61 administered subcutaneously 61 FTY# 61 antitumor effect 61 GLYX 61 BAY #-# 61 phase IIb 61 MDV# 61 PEGylated 61 Lu AA# 61 vandetanib 61 NP2 Enkephalin 61 Bicifadine 61 sulodexide 61 anticancer agent 61 CCR5 antagonist 61 Virulizin R 61 Phase 1b clinical 61 immune modulating 61 MOZOBIL 61 PROMACTA 61 Pemetrexed 61 monotherapy 61 diabetic neuropathic pain 61 GSK# [001] 61 tezampanel 61 CIMZIA TM certolizumab pegol 61 HDAC inhibitor 61 anticancer compound 61 phase Ib 61 Tβ4 61 JAK inhibitors 61 pharmacokinetic profile 61 DAVANAT 61 multicenter Phase II 61 HuLuc# 61 TRO# 61 Oritavancin 61 visilizumab 61 ACTEMRA TM 61 TPI ASM8 61 sunitinib 61 CG# [003] 61 Raptiva ® 61 Antiviral Activity 61 cell lymphoma CTCL 61 huN# DM1 61 RG# [001] 61 immunogenicity 61 sunitinib malate 61 tigecycline 61 APTIVUS 61 TACI Ig 61 AZILECT R 61 anti angiogenic 61 PKC# 61 TYZEKA 61 VNP#M 61 Vicinium TM 61 BAL# [001] 61 Tasimelteon 61 antitumor effects 61 Serdaxin 61 Japanese Encephalitis vaccine 61 Lubiprostone 61 MGd 61 Phase 2a clinical 61 somatostatin analogue 61 ASONEP 61 pharmacokinetic 61 Tyrima 61 efficacy tolerability 61 iclaprim 61 zalutumumab 61 belinostat 61 velafermin 61 TELINTRA 61 sorafenib tablets 61 Romidepsin 61 Cloretazine 61 EGFR inhibitors 61 partial agonist 61 TroVax ® 61 Curaxin CBLC# 61 antitumor 61 ALN TTR 61 polymerase inhibitor 61 Ocrelizumab 61 R#/MEM 61 Zybrestat 61 EZN 61 OHR/AVR# 61 depsipeptide 61 crizotinib PF # 61 nab paclitaxel 61 CANCIDAS 61 Allovectin 7 R 61 IAP inhibitors 61 docetaxel Taxotere R 61 MYDICAR ® 61 INGN 61 bortezomib 61 JAK2 inhibitors 61 BiTE 61 tolerability profiles 61 Microplasmin 61 Vilazodone 61 PEGylated Fab fragment 61 imatinib resistant 61 Panzem 61 OPAXIO 61 preclinical studies 61 preclinical efficacy 61 PNP inhibitor 61 blinatumomab 61 Phenoptin 61 orally bioavailable 61 Sapacitabine 61 Tovaxin 61 FOLOTYN ® 61 Vidaza azacitidine 61 Cethromycin 61 TRV# [001] 61 Omacetaxine mepesuccinate 61 TB4 61 fulvestrant 61 ISTODAX 61 imetelstat 61 DAS# [001] 61 mitogen activated ERK kinase 61 nanoviricides 61 CIMZIA ™ 60 pharmacokinetic PK profile 60 APOPTONE 60 pegylated 60 nonclinical studies 60 p# biomarker 60 ORMD 60 ELND# 60 Ceflatonin 60 RGB # 60 Angiolix 60 investigational monoclonal antibody 60 Valortim 60 GAP #B# 60 Cloretazine R 60 Reolysin 60 OMP #M# 60 Allovectin 7 ® 60 Seliciclib 60 MYLOTARG 60 oxidative stress inducer 60 MYCAMINE 60 ZADAXIN 60 PLX cells 60 HCV protease 60 aclidinium 60 ACZ# 60 PD LID 60 bortezomib Velcade 60 tivozanib 60 subcutaneous SC 60 LEP ETU 60 dose escalation trial 60 selective inhibition 60 IFN alpha 60 raltegravir 60 refractory gout 60 Bronchitol 60 G#DT 60 TELCYTA 60 Shigamabs ® 60 SUTENT 60 YONDELIS R 60 metaglidasen 60 dacetuzumab 60 Linaclotide 60 NEUGENE antisense 60 VA# [002] 60 G CSF 60 Phase 2b clinical 60 Glufosfamide 60 amrubicin 60 vemurafenib 60 generation purine nucleoside 60 Tavocept 60 baminercept 60 dasatinib 60 TNF α 60 zileuton 60 vosaroxin 60 UPLYSO 60 TKM ApoB 60 VEGF receptor 60 ZD# [001] 60 ADVANCE PD 60 dirucotide 60 relapsed multiple myeloma 60 pharmacokinetic PK study 60 sorafenib Nexavar 60 6R BH4 60 Amigal 60 CTCE 60 Interferon alpha 60 Vectibix monotherapy 60 Dalbavancin 60 placebo controlled Phase 60 pharmacodynamic markers 60 LY# [003] 60 Cimzia ® 60 voreloxin 60 immunostimulatory 60 telbivudine 60 tipifarnib 60 MAXY G# 60 Thiovir 60 Amplimexon 60 rilonacept 60 Annamycin 60 Rebif ® 60 SUTENT ® 60 oral FTY# 60 humanized antibody 60 ENMD 60 ritonavir boosted 60 Valortim ® 60 receptor inhibitor 60 daclizumab 60 selective kinase inhibitor 60 CRx 60 Ophena 60 QLT# 60 Increlex ® 60 Debio 60 investigational pan BCR 60 MAGE A3 ASCI 60 Aptivus ® 60 ANG# 60 Akt inhibitor 60 ANAVEX #-# [003] 60 ARIKACE 60 TYKERB 60 BIBW 60 RhuDex ® 60 CCR2 60 adecatumumab 60 docetaxel Taxotere ® 60 CGEN # 60 bevacizumab Avastin ® 60 EGFR HER2 60 BrachySil TM 60 adalimumab Humira 60 tasimelteon 60 AQ4N 60 novel anticancer 60 phase IIa 60 dosage regimens 60 trastuzumab DM1 T DM1 60 EGFr 60 cannabinor 60 Adalimumab 60 systemically administered 60 randomized discontinuation trial 60 Locteron 60 EOquin TM 60 IMP# 60 Preclinical studies suggest 60 XL# XL# 60 tocilizumab 60 cMET 60 Bavituximab 60 Phase 1a clinical 60 cetuximab Erbitux 60 phase IIb trial 60 Liposomal 60 Zalypsis 60 Arikace 60 ALN RSV# 60 immunomodulatory effects 60 Aurora kinase 60 Degarelix 60 cariprazine 60 HDAC 60 CD3 monoclonal antibody 60 Icatibant 60 Phase III Clinical Trials 60 antiviral efficacy 60 Betaferon ® 60 MEK inhibitor 60 intermittent dosing 60 Mipomersen 60 OMAPRO 60 urate lowering 60 GFT# 60 reslizumab 60 omacetaxine 60 NS#/#A protease 60 CCR9 60 interferon IFN 60 BiovaxID 60 WT1 60 Plicera 60 etanercept 60 Apoptone 60 Resten NG 60 hematologic malignancies 60 LymphoStat B 60 Fx #A 60 Voreloxin 60 fibrotic disease 60 farletuzumab 60 Epratuzumab 60 lumiliximab 60 ALK inhibitor 60 Increlex R 60 registrational trial 60 lupus nephritis 60 Safinamide 60 therapeutic monoclonal antibody 60 Aflibercept 60 Cotara 60 subcutaneously administered 60 HCV protease inhibitor 60 Atu# 60 TLR8 agonist 59 GRNVAC1 59 elvucitabine 59 rindopepimut 59 trabectedin 59 Gefitinib 59 AZD# 59 Lenocta 59 randomized Phase III 59 IDX# 59 oral rivaroxaban 59 INT# [002] 59 Diamyd ® 59 NVA# 59 CXB# 59 randomized controlled Phase 59 Radezolid 59 Taxotere ® 59 SERMs 59 AEZS 59 SRT# [003] 59 AZILECT ® 59 IAP inhibitor 59 mRCC 59 mGluR2 NAM 59 RLY# 59 Phase #b/#a clinical 59 cancer immunotherapies 59 ONCONASE R 59 ancrod 59 TRIOLEX 59 NeuroVax 59 Squalamine 59 galiximab 59 pharmacodynamic effects 59 hypoxia inducible factor 59 Alvesco R 59 Ambrisentan 59 NeuroVax TM 59 HDAC Inhibitor 59 tramiprosate Alzhemed TM 59 TG# [001] 59 REYATAZ R 59 Phase #b/#a trial 59 AeroLEF TM 59 TREANDA 59 lixisenatide 59 nucleoside analogs 59 replicon 59 tafamidis 59 REVLIMID 59 pharmacokinetics pharmacodynamics 59 pharmacokinetic interactions 59 FLT3 59 Pivotal Phase III 59 chemotherapeutic drug 59 Denosumab 59 TAFA# 59 evaluating tivozanib 59 Posiphen 59 Phase 1b trial 59 Aclidinium 59 kinase inhibition 59 Nanobody ® 59 talactoferrin 59 DOS# 59 AVE# 59 Anticalin ® 59 sJIA 59 virologic 59 sodium glucose cotransporter 59 ciclesonide 59 EOquin 59 potent anti angiogenic 59 imatinib therapy 59 DP b# 59 BRIM3 59 potent antiviral 59 Tocilizumab 59 Luteinizing Hormone Releasing Hormone 59 potent antitumor activity 59 gastrointestinal stromal tumors GIST 59 mTOR inhibitors 59 dosing regimens 59 pharmacokinetic properties 59 Genasense ® 59 tubulin inhibitor 59 RAPAFLO 59 Anticalin R 59 Nimotuzumab 59 antibody MT# 59 K ras mutations 59 Zolinza 59 SinuNase 59 Valsartan 59 Revimmune 59 docetaxel chemotherapy 59 Stedivaze 59 CRLX# 59 CDK inhibitors 59 kinase inhibitor 59 corticosteroid dexamethasone 59 hour bronchodilation 59 Erlotinib 59 induce apoptosis 59 ramelteon 59 safety tolerability pharmacokinetics 59 inhibitor RG# 59 clevidipine 59 Cetrorelix 59 TriRima 59 uricase 59 multi kinase inhibitor 59 multiple myeloma MM 59 rFVIIa 59 IMC #B 59 varespladib 59 vorinostat 59 preclinical models 59 HDAC inhibitors 59 nicotinic acetylcholine receptor 59 ALN TTR# 59 PEGylated interferon beta 1a 59 tipranavir 59 torezolid 59 Kahalalide F 59 EVIZON 59 AACR NCI EORTC 59 dose limiting toxicities 59 glufosfamide 59 CTLA 4 59 Maribavir 59 glioblastoma multiforme GBM 59 subcutaneous PRO 59 effector function 59 Zerenex 59 Eltrombopag 59 mGluR5 NAM 59 FGFR 59 ceftaroline 59 REP# 59 imatinib Gleevec ® 59 Advexin 59 golimumab 59 anti amnesic 59 antitumoral 59 fluticasone furoate 59 noninfectious uveitis 59 Candesartan 59 Nexavar ® 59 Glypromate 59 vivo potency 59 Pertuzumab 59 Yondelis ® 59 proteasome inhibitor bortezomib 59 peptibody 59 ZOLINZA 59 pitavastatin 59 GHRH 59 Preclinical studies 59 rALLy clinical trial 59 T#I [002] 59 humanised monoclonal antibody 59 Apaziquone 59 neuraminidase inhibitor 59 Tolvaptan 59 alvimopan 59 ADAGIO study 59 GMX# 59 bexarotene 59 TORISEL 59 proteasome inhibitor 59 tumor xenograft models 59 glatiramer acetate 59 combinability 59 LEUKINE 59 GV# [001] 59 Hsp# inhibitor 59 retapamulin 59 alefacept 59 #I TM# 59 SLx 59 FOLOTYN 59 Afatinib 59 TLK# 59 Nuvion 59 Fibrillex TM 59 celgosivir 59 Azedra TM 59 intratumoral injection 59 chemopreventive agent 59 alagebrium 59 ALKS 59 trabedersen 59 NOX E# 59 GM CSF 59 Xcytrin 59 XL# XL# XL# 59 LUX Lung 59 Romiplostim 59 Asentar 59 VEGFR2 59 bendamustine 59 PBT2 59 Quinamed 59 idraparinux 59 daptomycin 59 Eculizumab 59 bactericidal activity 59 Phase 2b study 59 Phase III randomized controlled 59 icatibant 59 TH# [003] 59 teplizumab 59 CD# monoclonal antibody 59 Octreolin 59 bevacizumab Avastin 59 ORENCIA R 59 novel histone deacetylase 59 BENLYSTA ® 59 Ophena TM 59 volociximab 59 orally dosed 59 dose escalation clinical 59 eprotirome 59 INC# 59 PrevOnco ™ 59 ZK EPO 59 GW# [003] 59 biologic therapy 59 tgAAC# 59 anti TNF alpha 59 RH1 59 pharmacodynamics 59 Tanespimycin 59 PI3K inhibitor 59 relapsed MM 59 Hsp# inhibitors 58 APPRAISE 58 Elagolix 58 E#F# 58 pharmacokinetic characteristics 58 recurrent glioblastoma multiforme 58 valopicitabine 58 Advagraf 58 lintuzumab 58 Randomized Phase 58 histone deacetylase HDAC 58 T DM1 58 docetaxel 58 miglustat 58 OvaRex R 58 Acute Ischemic Stroke 58 Aeroquin 58 EndoTAGTM 1 58 HER2 antibody 58 triphendiol 58 metastatic sarcoma 58 relapsed refractory multiple myeloma 58 PDX pralatrexate 58 potent inhibitor 58 ORENCIA ® 58 AMD# [003] 58 oral methylnaltrexone 58 Crofelemer 58 inecalcitol 58 anti angiogenic agent 58 Loramyc R 58 Multimeric 58 tesetaxel 58 immune modulatory 58 hepatocellular cancer 58 Cimzia TM 58 Decitabine 58 DDP# 58 Tolerability 58 cutaneous T cell 58 nicotinic alpha 7 58 cediranib 58 CUDC 58 tremelimumab 58 protease inhibitor PI 58 parathyroid hormone PTH 58 gefitinib 58 Nilotinib 58 masitinib 58 vascular disrupting 58 p# inhibitor 58 rHuPH# 58 myelofibrosis polycythemia vera 58 HIF PH inhibitors 58 MIRCERA 58 Guanilib 58 registrational 58 acyclovir Lauriad R 58 IPLEX 58 MetMAb 58 Vaprisol 58 rituximab Rituxan 58 custirsen 58 Vitaxin 58 TNFα 58 chemotherapy induced neutropenia 58 PEG interferon 58 novel peptide 58 HER2 positive metastatic breast 58 aflibercept VEGF Trap 58 demonstrated antitumor activity 58 TMC# [001] 58 Elesclomol 58 PEG PAL 58 Phase 2b trial 58 fluoropyrimidine 58 investigational hepatitis C 58 peptide antigens 58 Pathway Inhibitor 58 Spiegelmer ® 58 PMX # 58 Darusentan 58 LT NS# 58 gemcitabine Gemzar ® 58 Inhalation Solution 58 RNAi therapeutic targeting 58 safinamide 58 H#N# VLP vaccine 58 monoclonal antibody 58 Factor Xa inhibitor 58 GLPG# 58 HDACi 58 MEK inhibitor RDEA# 58 efalizumab 58 Talactoferrin 58 cyclin dependent kinases CDKs 58 randomized multicenter Phase III 58 Restanza 58 EFAPROXYN 58 Actemra tocilizumab 58 mg kg dose 58 CYT# potent vascular disrupting 58 antiangiogenic activity 58 Rasagiline 58 invasive candidiasis 58 refractory prostate cancer 58 vicriviroc 58 telaprevir VX 58 APTIVUS r 58 severe gastroparesis 58 Orazol 58 PDGFR 58 factor G CSF 58 SAR# [004] 58 perampanel 58 TEMODAL 58 GVAX 58 Scancell 58 xenograft models 58 Fulvestrant 58 BMS # 58 PTHrP 58 Zoledronic acid 58 SYN# 58 intravesical 58 Pafuramidine 58 DR Cysteamine 58 Morpholino 58 preclinical 58 Elocalcitol 58 topotecan 58 Lenalidomide 58 Personalized Immunotherapy 58 EGS# 58 Pegasys ® 58 HRPC 58 bardoxolone 58 ozarelix 58 protein kinase inhibitor 58 Zingo TM 58 pheochromocytoma 58 registrational studies